Background And Purpose: Tay-Sachs disease is a rare and often fatal, autosomal recessive, lysosomal storage disease. Deficiency in β-hexosaminidase leads to accumulation of GM2 ganglioside resulting in neuronal swelling and degeneration. Typical onset is in infancy with developmental regression and early death. Late-onset Tay-Sachs disease (LOTS) is extremely rare, especially in the non-Ashkenazi Jewish population, and is characterized by a more indolent presentation typically encompassing features of cerebellar and anterior horn cell dysfunction in addition to extrapyramidal and neuropsychiatric symptoms.

Cases: A case series of four unrelated patients of non-Ashkenazi Jewish origin with a predominantly, and in some cases pure, neuromuscular phenotype with evidence of a motor neuronopathy on electromyography is presented. Cerebellar atrophy, reported to be a ubiquitous feature in LOTS, was absent in all patients.

Conclusion: This case series provides evidence to support a pure neuromuscular phenotype in LOTS, which should be considered in the differential diagnosis of anterior horn cell disorders.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235873PMC
http://dx.doi.org/10.1111/ene.16069DOI Listing

Publication Analysis

Top Keywords

tay-sachs disease
12
case series
12
late-onset tay-sachs
8
non-ashkenazi jewish
8
anterior horn
8
horn cell
8
pure neuromuscular
8
neuromuscular phenotype
8
disease
4
disease presenting
4

Similar Publications

Tay-Sachs disease is a fatal neurodegenerative disorder caused by mutations inactivating the metabolic enzyme HexA. The most common mutation is c.1278insTATC, a tandem 4-bp duplication disrupting expression by frameshift.

View Article and Find Full Text PDF

The GM2 gangliosidoses, Tay-Sachs disease and Sandhoff disease, are devastating neurodegenerative disorders caused by β-hexosaminidase A (HexA) deficiency. In the Sandhoff disease mouse model, rescue potential was severely reduced when HexA was introduced after disease onset. Here, we assess the effect of recombinant HexA and HexD3, a newly engineered mimetic of HexA optimized for the treatment of Tay-Sachs disease and Sandhoff disease.

View Article and Find Full Text PDF

Clinical and biochemical abnormalities in a feline model of GM2 activator deficiency.

Mol Genet Metab

November 2024

Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, AL 36849, United States of America; Department of Anatomy, Physiology & Pharmacology, College of Veterinary Medicine, Auburn University, AL 36849, United States of America. Electronic address:

Though it has no catalytic activity toward GM2 ganglioside, the GM2 activator protein (GM2A) is essential for ganglioside hydrolysis by facilitating the action of lysosomal ß-N-acetylhexosaminidase. GM2A deficiency results in death in early childhood due to rapid central nervous system deterioration similar to the related GM2 gangliosidoses, Tay-Sachs disease and Sandhoff disease. This manuscript further characterizes a feline model of GM2A deficiency with a focus on clinical and biochemical parameters that may be useful as benchmarks for translational therapeutic research.

View Article and Find Full Text PDF

Genetic testing identified novel compound heterozygous missense variants in the HEXA gene (NM_00520.6: c.775A>C and NM_000520.

View Article and Find Full Text PDF

Beyond the traditional distinctions of genome editing: evaluating a vulnerability framework.

Front Genome Ed

October 2024

Research Unit "Ethics of Genome Editing", Institute of Ethics and History of Medicine, University of Tübingen, Tübingen, Germany.

Article Synopsis
  • The 1982 Splicing Life report established key distinctions in genetic intervention: somatic vs. germline (heritable) and medical vs. non-medical (enhancement) applications, which have since shaped the ethical and legal frameworks in this field.
  • While somatic treatments are often favored, some controversies arise when they are used for enhancement, and the justification for germline interventions varies based on context (e.g., disease prevention vs. enhancement).
  • The paper argues for shifting the focus from whether technologies should be used to how they should be used, emphasizing the importance of addressing vulnerability and marginalization to guide effective global governance and policy development.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!